Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20913335 | 0.89 | HCAR3 (0.56) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL1702183 | 0.81 | RAB9A (0.49) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL1702156 | 0.79 | ALOX15 (0.46) | KDM4EMAPTRAB9ALMNAGAA | |
| SCHEMBL64414 | 0.76 | HCAR3 (0.71) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL25894269 | 0.76 | KMT2A (0.56) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL25853749 | 0.76 | KDM4E (0.46) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL2850453 | 0.75 | KMT2A (0.72) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL17010816 | 0.75 | MEN1 (0.55) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL14420787 | 0.75 | MEN1 (0.65) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL6984008 | 0.74 | HCAR3 (0.68) | KDM4EMAPTKMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | claimed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| EP-2440547-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| EP-2440545-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2024-10-17 | — | — | US | disclosed |
| EP-3517534-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| EP-3521283-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| EP-4198022-A1 | PREPARATION OF COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198022-A1 | PREPARATION OF COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2023-06-21 | — | — | EP | disclosed |
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | disclosed |
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | disclosed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | disclosed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | disclosed |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2022-04-28 | — | — | US | disclosed |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2022-04-28 | — | — | US | disclosed |
| EP-3016656-B1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2021-09-08 | — | — | EP | disclosed |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | ABIVAX (FR) | 2021-05-25 | — | — | US | disclosed |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | ABIVAX (FR) | 2021-05-25 | — | — | US | disclosed |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | ABIVAX (FR) | 2021-04-13 | — | — | US | disclosed |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | ABIVAX (FR) | 2021-04-13 | — | — | US | disclosed |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | ABIVAX (FR) | 2020-06-16 | — | — | US | disclosed |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | ABIVAX (FR) | 2020-06-16 | — | — | US | disclosed |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | ABIVAX (FR) | 2020-06-04 | — | — | US | disclosed |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | ABIVAX (FR) | 2020-06-04 | — | — | US | disclosed |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | ABIVAX (FR) | 2019-10-24 | — | — | US | disclosed |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | ABIVAX (FR) | 2019-10-24 | — | — | US | disclosed |
| EP-3521283-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521283-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-08-07 | — | — | EP | disclosed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | disclosed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | disclosed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | disclosed |
| EP-2440545-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-04-24 | — | — | EP | disclosed |
| US-10253020-B2 | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | ABIVAX (FR) | 2019-04-09 | — | — | US | disclosed |
| US-10253020-B2 | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | ABIVAX (FR) | 2019-04-09 | — | — | US | disclosed |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2018-11-29 | — | — | US | disclosed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | disclosed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | disclosed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | disclosed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | disclosed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | disclosed |
| US-9908869-B2 | Compounds useful for treating aids | ABIVAX (FR) | 2018-03-06 | — | — | US | disclosed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | disclosed |
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2017-08-10 | — | — | US | disclosed |
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2017-08-10 | — | — | US | disclosed |
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2017-08-10 | — | — | US | disclosed |
| US-9637475-B2 | Compounds for treating cancer | ABIVAX (FR) | 2017-05-02 | — | — | US | disclosed |
| US-9637475-B2 | Compounds for treating cancer | ABIVAX (FR) | 2017-05-02 | — | — | US | disclosed |
| US-9637475-B2 | Compounds for treating cancer | ABIVAX (FR) | 2017-05-02 | — | — | US | disclosed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | disclosed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | disclosed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | disclosed |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-22 | — | — | US | disclosed |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-22 | — | — | US | disclosed |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-22 | — | — | US | disclosed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | disclosed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | disclosed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | disclosed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | disclosed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | disclosed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | disclosed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | disclosed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2014-09-25 | — | — | US | disclosed |
| CN-103948594-A | Compounds for the treatment of cancer | SPLICOS SOC | 2014-07-30 | — | — | CN | disclosed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | disclosed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | disclosed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | disclosed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | disclosed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | disclosed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | disclosed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | disclosed |
| EP-2440547-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | Société Splicos (FR) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885MAPT 3932/4885MEN1 2482/4885 |
| US-10017498-B2 | Compounds useful for treating AIDS | NR1H3, NR1H2, NR1H4 | KDM4E 3991/4885MAPT 4010/4885MEN1 3719/4885 |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | KDM4E 3299/4885MAPT 4329/4885MEN1 3647/4885 |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885MAPT 3932/4885MEN1 2482/4885 |
| US-20140288120-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR3C1, NR3C2 | KDM4E 3904/4885MAPT 4252/4885MEN1 3480/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | KDM4E 2650/4885MAPT 4736/4885MEN1 1925/4885 |
| US-11014918-B2 | Compounds and pharmaceutical compositions containing at least one of the compounds | TP53, BRCA1, LIMS1 | KDM4E 2378/4885MAPT 271/4885MEN1 663/4885 |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885MAPT 3932/4885MEN1 2482/4885 |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | CXCL8, FURIN, ABL1 | KDM4E 420/4885MAPT 1077/4885MEN1 2356/4885 |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | KDM4E 3841/4885MAPT 4658/4885MEN1 2379/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | KDM4E 3675/4885MAPT 4162/4885MEN1 3042/4885 |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR1H2, NR1H4 | KDM4E 3991/4885MAPT 4010/4885MEN1 3719/4885 |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885MAPT 3932/4885MEN1 2482/4885 |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885MAPT 3932/4885MEN1 2482/4885 |
| US-10253020-B2 | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | RCOR1, NR3C1, NR5A1 | KDM4E 3655/4885MAPT 3932/4885MEN1 2482/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | KDM4E 2880/4885MAPT 3658/4885MEN1 2704/4885 |
| US-20200172525-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THE COMPOUNDS | TP53, BRCA1, LIMS1 | KDM4E 2378/4885MAPT 271/4885MEN1 663/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | KDM4E 3883/4885MAPT 4707/4885MEN1 1720/4885 |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | CXCL8, FURIN, ABL1 | KDM4E 420/4885MAPT 1077/4885MEN1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.